Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 36.9% during the 4th quarter, Holdings Channel reports. The firm owned 42,650 shares of the specialty pharmaceutical company’s stock after buying an additional 11,490 shares during the period. State of Alaska Department of Revenue’s holdings in Supernus Pharmaceuticals were worth $2,119,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in SUPN. Hantz Financial Services Inc. boosted its stake in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the last quarter. USA Financial Formulas acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $50,000. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 268 shares during the last quarter. Vestcor Inc acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at about $67,000. Finally, State of Wyoming acquired a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $68,000.

Supernus Pharmaceuticals Stock Up 4.4%

Shares of Supernus Pharmaceuticals stock opened at $51.39 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68. The business has a fifty day simple moving average of $51.40 and a 200-day simple moving average of $49.83. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -75.57, a price-to-earnings-growth ratio of 1.53 and a beta of 0.73.

Insider Activity

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total value of $228,269.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 7,250 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total value of $359,600.00. Following the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 120,881 shares of company stock valued at $6,139,356 in the last ninety days. 8.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.